The Food and Drug Administration has opened a safety review of sevoflurane and other general anesthetics, and the phrasing of the announcement is doing a lot of work that headlines can easily flatten.
In an alert issued on July 2, the agency said it is investigating the safety of sevoflurane and other general anesthetics based on published scientific reports of catastrophic outcomes, including severe neurologic injury and death, in adult and pediatric patients of maternal Venezuelan ancestry after routine general anesthesia. The immediate trigger was practical: after recent earthquakes in Venezuela, the FDA wanted agencies sending medical resources and clinicians traveling to the country to know about these rare events.
For the overwhelming majority of Americans scheduled for surgery this month, this alert does not change anything. For a small number of families, it is a conversation to have with an anesthesiologist before the procedure.
What the Reports Actually Describe
A rare mitochondrial genetic variant, MT-ND4 m.11232T>C, has been reported in a subset of patients who experienced serious adverse events after sevoflurane exposure. FDA noted that while the reported cases involve sevoflurane, the variant "raises concerns regarding all volatile anesthetics."
The biology is specific. ND4 is a subunit of complex I of the mitochondrial electron transport chain, and complex I is a known target of volatile anesthetics. The Anesthesia Patient Safety Foundation has explained that propofol also interacts with complex I, so the relative safety of intravenous agents in these patients is not established either. All patients in the reported cases were homoplasmic, meaning essentially all of their mitochondria carried the variant.
The clinical picture described in the literature includes basal ganglia injury and death in people who were previously healthy and who had no signs of mitochondrial disease before anesthesia.
This did not surface first at the FDA. The American Society of Anesthesiologists and the Society for Pediatric Anesthesia issued a joint communication in January. A report from the Chilean Ministry of Health was published in Anesthesiology in February. European anesthesiology and mitochondrial disease groups issued a joint statement in March. Additional cases have since been identified in Europe and the United States.
MedicalDaily Evidence Check
The evidence here is case reports and case series, assembled across several countries, plus genetic testing on a subset of affected patients. It is not a controlled study, and it does not establish that the variant causes these outcomes. Researchers describe a plausible mechanism and a striking pattern, which is enough to warrant caution and further investigation, and not enough to change the safety profile of anesthesia for the general population.
Two limitations matter most. The variant has been classified as of uncertain clinical significance under standard genetics interpretation guidelines, and some laboratories historically treated it as a benign polymorphism. Family histories are inconsistent: some relatives of affected patients had adverse events, while others had uneventful anesthetics, which suggests other factors are involved.
FDA has not restricted sevoflurane, changed labeling, or recommended any change for U.S. patients generally. It said it is continuing to review the concern for implications for the U.S. population and for approved anesthetic products.
Who This Could Apply To
The reported cases involve maternal Venezuelan ancestry. Because mitochondrial DNA is inherited only from the mother, the relevant question is the maternal line specifically, meaning mother, maternal grandmother, and their relatives.
Recent genetic analyses suggest the variant may define a previously uncharacterized sub-lineage found in certain Indigenous American populations, particularly those tracing maternal ancestry to Venezuela. That is an active area of research rather than a settled finding.
The other group with a reason to raise this is anyone with a known mitochondrial disorder, or a family history of an unexplained catastrophic outcome after anesthesia. That history has always been worth reporting before surgery, and it is more clearly relevant now.
What Anesthesiologists Have Been Told
Professional societies have been explicit that guidance is preliminary. The Society for Pediatric Anesthesia communication says the recommendations were issued in a situation where "much more is unknown than known."
Where testing is accessible, clinicians may consider mitochondrial DNA sequencing for patients with Venezuelan maternal ancestry before planned surgery, with informed consent. Routine population-wide screening is not recommended by any group. For patients considered potentially at risk without definitive results, societies have suggested considering avoidance of volatile anesthetics until more is known, weighed against the urgency of the procedure.
FDA's own suggestion was narrower and geographically targeted: agencies providing medical resources to Venezuelans and clinicians working in Venezuela may consider intravenous or regional anesthesia where clinically appropriate and available.
What Patients Should Do Before Surgery
Do not cancel or delay a needed operation over this alert. The risk described applies to a rare variant in a specific maternal lineage, and untreated surgical disease carries its own well-documented harm.
Do tell the anesthesiologist about maternal ancestry from Venezuela, any known mitochondrial disorder in the family, and any relative who had an unexplained severe reaction, prolonged recovery or neurologic injury after anesthesia. Pre-anesthesia interviews already ask about family reactions to anesthesia, and this is the moment to give a detailed answer rather than a short one.
Do not seek direct-to-consumer genetic testing to answer this question. Consumer ancestry panels are not clinical mitochondrial sequencing, and interpreting the result requires a clinical geneticist or mitochondrial disease specialist.
This article is general information and not medical advice. Decisions about anesthetic technique belong to a patient and their anesthesia team.
What Happens Next
FDA said it is continuing its review and encouraged clinicians and patients to report adverse events through MedWatch. Anesthesiology societies in the United States and Europe have signaled that further joint guidance on genetic testing and perioperative management is in preparation.
The most useful near-term development would be a defined estimate of how common the variant is in populations of Venezuelan descent, which would let clinicians weigh testing against the delay it introduces. That number does not yet exist publicly. MedicalDaily will follow the FDA review and any labeling action.
Frequently Asked Questions
Is anesthesia unsafe now? No. FDA has opened a review of rare cases linked to a specific mitochondrial variant. It has not restricted sevoflurane or changed general guidance for U.S. patients.
Who is potentially affected? Patients with maternal Venezuelan ancestry in the reported cases, and more broadly anyone with a known mitochondrial disorder or a family history of catastrophic reaction to anesthesia.
Why does maternal ancestry matter specifically? Mitochondrial DNA is inherited from the mother only, so the variant passes down the maternal line.
Should I get genetic testing before surgery? No group recommends routine population screening. Testing may be considered for people with Venezuelan maternal ancestry where it is accessible, with guidance from a clinician.
Is propofol a safe alternative? Not established. Propofol also interacts with mitochondrial complex I, and societies have said the relative risks are unknown.
What should I tell my anesthesiologist? Your maternal family origin, any mitochondrial diagnosis, and any relative who had a severe or unexplained reaction to anesthesia.
Does this relate to older warnings about anesthesia and children's brains? No. That separate 2016 labeling issue concerned repeated or lengthy anesthesia in children under three. This alert is about a rare genetic susceptibility.
